Akums Drugs & Pharmaceuticals Share Price
₹668.40 +60.75 (10%)
28 Dec, 2024 01:21
Start SIP in AKUMS
Start SIPPerformance
- Low
- ₹608
- High
- ₹668
- 52 Week Low
- ₹530
- 52 Week High
- ₹1,176
- Open Price₹613
- Previous Close₹608
- Volume2,105,937
Investment Returns
- Over 1 Month + 4.17%
- Over 3 Month -19.64%
- Over 6 Month -1.56%
- Over 1 Year -1.56%
Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!
Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 37.9
- PEG Ratio
- -
- Market Cap Cr
- 10,520
- P/B Ratio
- 14.6
- Average True Range
- 32.29
- EPS
- 17.41
- Dividend Yield
- 0
- MACD Signal
- -33.3
- RSI
- 59.12
- MFI
- 76.97
Akums Drugs & Pharmaceuticals Financials
Akums Drugs & Pharmaceuticals Technicals
EMA & SMA
Current Price
₹668.40
+
60.75
(10%)
- Bullish Moving Average 9
- Bearish Moving Average 2
- 20 Day
- ₹614.26
- 50 Day
- ₹680.21
- 100 Day
- -
- 200 Day
- -
Resistance and Support
648.28
- R3 748.87
- R2 708.63
- R1 688.52
- S1 628.17
- S2 587.93
- S3 567.82
Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-09 | Quarterly Results | |
2024-08-24 | Quarterly Results |
Akums Drugs & Pharmaceuticals F&O
About Akums Drugs & Pharmaceuticals
- NSE Symbol
- AKUMS
- BSE Symbol
- 544222
- Managing Director
- Mr. Sanjeev Jain
- ISIN
- INE09XN01023
Similar Stocks to Akums Drugs & Pharmaceuticals
Akums Drugs & Pharmaceuticals FAQs
Akums Drugs & Pharmaceuticals share price is ₹668 As on 28 December, 2024 | 01:07
The Market Cap of Akums Drugs & Pharmaceuticals is ₹10520.2 Cr As on 28 December, 2024 | 01:07
The P/E ratio of Akums Drugs & Pharmaceuticals is 37.9 As on 28 December, 2024 | 01:07
The PB ratio of Akums Drugs & Pharmaceuticals is 14.6 As on 28 December, 2024 | 01:07
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.